Non-Valvular Atrial Fibrillation
Conditions
Brief summary
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin or apixaban or dabigatran or rivaroxaban treatment.
Interventions
None listed
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Had 1 or more pharmacy claim for apixaban or warfarin or dabigatran or rivaroxaban during the identification period (01-Jan-2013 to 30-Sep-2015). The first OAC pharmacy claim date during the identification period will be designated as the index date 2. Patients 18 years old or older as of the index date 3. At least 1 diagnosis of atrial fibrillation prior to or on index date, identified by any medical claim 4. At least 12 months of baseline period prior to index date with continuous enrollment
Exclusion criteria
1. Evidence of valvular heart disease, transient atrial fibrillation, venous thromboembolism during the 12-month baseline period or on the index date 2. Evidence of pregnancy during the study period 3. Had a pharmacy claim for warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban during the 12-month baseline period 4. Had more than 1 oral anticoagulant claim on the index date
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to first major bleeding event | Up to 33 months |
| Time to first stroke/systemic embolism (SE) event | Up to 33 months |
Secondary
| Measure | Time frame |
|---|---|
| Major bleeding-related medical costs | Up to 33 months |
| Stroke/SE-related medical costs | Up to 33 months |
| All-cause Healthcare costs | Up to 33 months |
Countries
United States
Outcome results
None listed